Zdrowie i gospodarka · 26/10/2005

FDA Publishes Guidance for CFTR Gene Mutation Detection Systems

The FDA has released a guidance document outlining requirements for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection systems, which are classified as Class II devices, and must comply with special controls. The guidance is effective immediately and invites public comment.